Newly IPO’d Medpace sees Q3 revenue jump

Medpace ($MEDP) saw net service revenue hit $94.8 million for Q3, a jump of 16.1% compared to last year, as it enjoys life after its $160 million summer IPO.

The Cincinnati, OH-based CRO’s backlog at the end of September grew 14% to $480.4 million, while net new business awards were $109.1 million, representing a net book-to-bill ratio of 1.15x, for the third quarter.

Looking at the last nine months, net new business awards were $327.2 million, representing a book-to-bill ratio of 1.19x.

Featured Webinar

From Concept to Market: Overcoming the Challenges of Manufacturing and Clinical Trials

In this webinar we will reveal the inner workings of the manufacturing and pharmacy department of a CRO/CDMO, so you understand the different regulatory and operational considerations faced by a clinical research pharmacy.

Learn how CRO/CDMOs successfully address operational and regulatory challenges for pharmaceutical and biotechnology clients; and how this can make the difference between study success or failure.

These past three quarters were up on last year’s given its growth in oncology, CV and antiviral anti-infective therapeutic areas, the company said.

During Q3, Medpace also used the net proceeds from its IPO, as well as its available cash, to repay $210 million worth of loans, lowering its debt to $165 million.

The CRO’s cash and cash equivalents were $14.6 million at Sept. 30, 2016, while it made $42.2 million in cash flow from operating activities during Q3.

Medpace, which has a market cap of $1.29 billion, was up 2.4% on Monday, with its shares worth $31.72. It sold 8 million of its shares in its IPO back in mid-August for $23 apiece.  

Read more on

Suggested Articles

Matching the right patients to the right trials is a key piece of the recruitment puzzle. In oncology, it can be life and death.

U.K.-based CRO Sygnature Discovery is buying up fellow native life science services provider XenoGesis in order to boost its preclinical offerings.

PRA Health is tapping Deep Lens and the Microsoft Azure platform in matchmaking cancer patients to the right trials to speed up recruitment.